Figure 6.
Figure 6. Progression-free survival (PFS) assessed according to genetic markers in the multicenter prospective CLL1 trial of the GCLLSG26,28 (see also www.dcllsg.de). / A) According to VH mutation status. / B) According to genomic aberrations

Progression-free survival (PFS) assessed according to genetic markers in the multicenter prospective CLL1 trial of the GCLLSG26,28 (see also www.dcllsg.de).

A) According to VH mutation status

B) According to genomic aberrations

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal